404

Not Found

Is this what you were looking for?

index php best price for generic cialis lib modules index php
By Amy Swinderman

Forming a pharma fund

Index Ventures, GSK and J&J align to make $240 million in venture-capital funding available to life-science companies with early-stage assets
By Amy Swinderman

Merck and Schering-Plough to merge in $41.1 billion deal

WHITEHOUSE STATION, N.J.—Increasing generic competition and pricing pressures united two more of the world’s largest pharmaceutical players this week, as Merck & Co. announced on Monday it will buy Schering-Plough in a $41.1 billion stock-and-cash deal that some industry veterans are calling “the mating of dinosaurs.”
By Kimberely Sirk

Expanding the Spectrum

Small but up-and-coming pharma to work toward biosimilar rituximab with Viropro
By Amy Swinderman

Sanofi pulls the plug on 13 clinical programs, ramps up M&A efforts

Amidst its report of a good first-quarter performance, Sanofi-aventis announced late last month a dramatic makeover of its R&D pipeline, including the abandonment of several late-stage drug programs, and continued its recent acquisition streak with the purchase of an oncology-focused company in California.
By Arthur J. Hiller, SciFluor

Finding the right balance

If you’ve ever met with a financial planner or investment advisor, then you know that one of the first rules of investing is diversification, an important risk management technique that ensures there are a variety of assets within a portfolio. As biopharmaceutical organizations, it is important that we recognize the dire consequences that may result if we ignore this proven strategy.

Run a Search

March 2024 Issue Front Cover

Latest Issue  

• Volume 20 • Issue 2 • March 2024

March 2024

March 2024 Issue